It was observed that serum miR-122 had a robust potential to discriminate CHC patients (including both normal and elevated ALT patients) from healthy controls with an area under the curve (AUC) of 0.954 (95% CI: 0.907–0.981; P < 0.0001). The gene discussed is GPT; the disease is cryohydrocytosis.